Drug Trial Radar · NCT05121714
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Dec 17, 2020
Primary completion
May 18, 2021
Study completion May 18, 2021
Sponsor
- Lead sponsor
- Abivax S.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A two part, fixed-sequence, open-label crossover study to evaluate potential CYP1A2-mediated drug-drug interactions of ABX464 in healthy subjects using caffeine and fluvoxamine as probe drugs
Conditions
- Healthy
Interventions
CaffeineDrug
This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)
ABX464Drug
This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).
FluvoxamineDrug
This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A - Day 1 Peak Plasma Concentration of CaffeineTime frame: Day 1
- Part A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464Time frame: Day 4
- Part A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464Time frame: Day 17
- Part A - Day 1 AUC of CaffeineTime frame: Day 1
- Part A - Day 4 AUC of Caffeine & ABX464Time frame: Day 4
- Part A - Day 17 AUC of Caffeine & ABX464Time frame: Day 17
- Part B - Day 1 - Peak Plasma Concentration of ABX464Time frame: Day 1
- Part B - Day 11 - Peak Plasma Concentration of ABX464Time frame: Day 11
- Part B - Day 1 - Area Under the Plasma Concentration Versus Time Curve (AUC)Time frame: Day 1
- Part B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)Time frame: Day 11
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Simbec-Orion
Merthyr Tydfil, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.